Susan L Woulfe

US Patent:

6967092, Nov 22, 2005

Filed:

Oct 24, 1997

Appl. No.:

08/957610

Inventors:

John P. Mc Kearn - Glencoe MO, US
Charles A. McWherter - Wildwood MO, US
Yiqing Feng - St. Louis MO, US
Neena L. Summers - St. Charles MO, US
Nicholas R. Staten - St. Louis MO, US
Philip R. Streeter - Glencoe MO, US
Susan L. Woulfe - Ballwin MO, US
Nancy I. Minster - Chesterfield MO, US
John C. Minnerly - St. Louis MO, US

International Classification:

C07K019/00
C12N001/21
C12N005/10
C12N015/62

US Classification:

435 697, 435 694, 435 695, 435455, 435325, 4352523, 4353201, 530350, 530351, 536 234, 536 235, 536 2351

Abstract:

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proetiens and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.

US Patent:

20040127410, Jul 1, 2004

Filed:

Aug 20, 2003

Appl. No.:

10/644355

Inventors:

Charles McWherter - Wildwood MO, US
Yiqing Feng - St. Louis MO, US
John McKearn - Glencoe MO, US
Nicholas Staten - St. Louis MO, US
Philip Streeter - Glencoe MO, US
Susan Woulfe - Ballwin MO, US
Nancy Minster - Chesterfield MO, US
John Minnerly - St. Louis MO, US

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.

US Patent:

20050042219, Feb 24, 2005

Filed:

Dec 5, 2003

Appl. No.:

10/728420

Inventors:

Susan Woulfe - Woodbury MN, US
Rita Jain - Roslyn Harbor NY, US
Aimee Burr - Chicago IL, US

International Classification:

A61K039/395
A61K031/525

US Classification:

424145100, 514251000

Abstract:

The present invention provides a combination therapeutic composition useful in modulating, treating and/or preventing inflammatory diseases. The therapeutic composition includes antibody Fab′ fragment CDP870 that is specific for antigenic determinants of tumor necrosis factor alpha and at least one Disease Modifying Anti-Rheumatic Disease drug such as methotrexate or sulfasalazine. The therapeutic composition can be administered to either a human or animal subject in single or multiple doses over time in the treatment of rheumatoid arthritis, Crohn's Disease or any other inflammatory disease.

US Patent:

20070081979, Apr 12, 2007

Filed:

Apr 5, 2005

Appl. No.:

11/099263

Inventors:

John Mc Kearn - Glencoe MO, US
Charles McWherter - Wildwood MO, US
Yiqing Feng - St. Louis MO, US
Neena Summers - St. Charles MO, US
Nicholas Staten - St. Louis MO, US
Philip Streeter - Glencoe MO, US
Susan Woulfe - Ballwin MO, US
Nancy Minster - Chesterfield MO, US
John Minnerly - St. Louis MO, US

International Classification:

A61K 45/00
C07H 21/04
C12N 5/08
C07K 14/71

US Classification:

424093700, 530350000, 435069100, 435320100, 435372000, 536023500

Abstract:

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proteins and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.

US Patent:

6660257, Dec 9, 2003

Filed:

Oct 21, 1997

Appl. No.:

08/955090

Inventors:

Charles A. McWherter - Wildwood MO
Yiqing Feng - St. Louis MO
John P. Mc Kearn - Glencoe MO
Nicholas R. Staten - St. Louis MO
Philip R. Streeter - Glencoe MO
Susan L. Woulfe - Ballwin MO
Nancy I. Minster - Chesterfield MO
John C. Minnerly - St. Louis MO

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K 3819

US Classification:

424 851, 4241981, 530351, 530399, 514 2, 514 12

Abstract:

Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.

US Patent:

20220189632, Jun 16, 2022

Filed:

Oct 3, 2019

Appl. No.:

17/436743

Inventors:

- St. Paul MN, US
Gilles J. Benoit - Minneapolis MN, US
Peter O. Olson - Andover MN, US
Tyler W. Olson - Woodbury MN, US
Himanshu Nayar - St. Paul MN, US
Frederick J. Arsenault - Stillwater MN, US
Nicholas A. Johnson - Burnsville MN, US
Susan L. Woulfe - Woodbury MN, US
Mark A. Tomai - Hudson WI, US

International Classification:

G16H 50/20
G16H 50/50
G16H 20/10
A61B 5/00
A61B 5/0205
A61B 5/021
A61B 5/024
A61B 5/145
A61M 16/00

Abstract:

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting settings for a treatment of a patient. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for providing a treatment to a patient based on a causal model that measures current causal relationships between input settings and effects of treatments on the patient; ii) receiving a measure of an effect of the treatment on the patient; and iii) adjusting, based on the measure of the effect of the treatment on the patient, the causal model.

US Patent:

20220178899, Jun 9, 2022

Filed:

Oct 3, 2019

Appl. No.:

17/436770

Inventors:

- St. Paul MN, US
Gilles J. Benoit - Minneapolis MN, US
Peter O. Olson - Andover MN, US
Tyler W. Olson - Woodbury MN, US
Himanshu Nayar - St. Paul MN, US
Frederick J. Arsenault - Stillwater MN, US
Nicholas A. Johnson - Woodbury MN, US
Susan L. Woulfe - Woodbury MN, US
Mark A. Tomai - Hudson WI, US

International Classification:

G01N 33/15
G05B 13/04
B01J 19/00

Abstract:

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for optimizing a process of manufacturing a biologic pharmaceutical. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for manufacturing a batch of a biologic pharmaceutical based on a causal model that measures current causal relationships between input settings and a measure of a quality of batches of the biological pharmaceutical; ii) determining a measure of the quality of a batch of the biological pharmaceutical manufactured using the configuration of input settings; and iii) adjusting, based on the measure of the quality of the batch of the biological pharmaceutical, the causal model.

US Patent:

20220180979, Jun 9, 2022

Filed:

Oct 28, 2019

Appl. No.:

17/436840

Inventors:

- St. Paul MN, US
Gilles J. Benoit - Minneapolis MN, US
Peter O. Olson - Andover MN, US
Tyler W. Olson - Woodbury MN, US
Himanshu Nayar - St. Paul MN, US
Frederick J. Arsenault - Stillwater MN, US
Nicholas A. Johnson - Woodbury MN, US
Susan L. Woulfe - Woodbury MN, US
Mark A. Tomai - Hudson WI, US

International Classification:

G16H 10/20
G16H 50/70

Abstract:

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for designing a clinical trial. In one aspect, the method comprises repeatedly performing the following: i) selecting, from a population of patients, patients for being treated with the treatment using a configuration of input settings, wherein the configuration is selected based on a causal model that measures current causal relationships between input settings and a measure of success of the clinical trial; ii) determining the measure of success of the clinical trial for which patients were selected using the certain configuration of input settings; and iii) adjusting, based on the measure of success of the clinical trial, the causal model.